Amicus Therapeutics, Inc. $FOLD Shares Sold by Swiss National Bank

Swiss National Bank decreased its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 0.8% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 434,200 shares of the biopharmaceutical company’s stock after selling 3,300 shares during the period. Swiss National Bank owned approximately 0.14% of Amicus Therapeutics worth $3,543,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Headlands Technologies LLC increased its position in Amicus Therapeutics by 61.0% during the 1st quarter. Headlands Technologies LLC now owns 56,030 shares of the biopharmaceutical company’s stock worth $457,000 after purchasing an additional 21,218 shares during the period. Deutsche Bank AG increased its position in Amicus Therapeutics by 26.4% during the 1st quarter. Deutsche Bank AG now owns 1,038,990 shares of the biopharmaceutical company’s stock worth $8,478,000 after purchasing an additional 216,882 shares during the period. Legacy Capital Group California Inc. grew its holdings in shares of Amicus Therapeutics by 16.2% in the 1st quarter. Legacy Capital Group California Inc. now owns 26,993 shares of the biopharmaceutical company’s stock worth $220,000 after acquiring an additional 3,764 shares during the period. PNC Financial Services Group Inc. increased its stake in Amicus Therapeutics by 211.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 5,151 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 3,497 shares in the last quarter. Finally, Jefferies Financial Group Inc. purchased a new position in Amicus Therapeutics in the 1st quarter valued at approximately $1,533,000.

Analysts Set New Price Targets

Several research firms recently weighed in on FOLD. UBS Group raised their price objective on Amicus Therapeutics from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Friday, May 2nd. The Goldman Sachs Group dropped their price objective on Amicus Therapeutics from $12.00 to $9.00 and set a “neutral” rating for the company in a research note on Friday, May 2nd. Wall Street Zen raised Amicus Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd. Finally, Morgan Stanley raised Amicus Therapeutics from an “equal weight” rating to an “overweight” rating in a research note on Thursday, July 17th. Eight equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, Amicus Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $16.22.

Amicus Therapeutics Price Performance

Shares of NASDAQ:FOLD opened at $7.40 on Thursday. The business’s fifty day moving average price is $6.29 and its two-hundred day moving average price is $7.23. The stock has a market cap of $2.28 billion, a PE ratio of -61.66 and a beta of 0.53. The company has a debt-to-equity ratio of 1.92, a quick ratio of 2.29 and a current ratio of 3.21. Amicus Therapeutics, Inc. has a one year low of $5.51 and a one year high of $12.65.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.